EUVIMEDEUVIMED entdecken
Crossref

Methylation of Interleukin-1 receptor-associated kinase-3 and the risk of multiple sclerosis relapse/activity

Mona M Watany, Marwa M Elhosary, Hemat E El-Horany, Mahmoud E El-Horany

Clinical Immunology · 2024-09 · 266 · 110327

DOI: 10.1016/j.clim.2024.110327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2024-09. Verfasst von Mona M Watany und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical pathology department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Electronic address: mona.watany@med.tanta.edu.eg. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Multiple Sclerosis, Myeloid Differentiation Factor 88. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study retrospectively investigated the impact of interleukin-1 receptor-associated kinase-3 (IRAK-3/IRAK-M) silencing by methylation on the likelihood of multiple sclerosis (MS) activity. This cross-sectional study included 90 patients with MS: 45 with active disease (Group 1), 45 in remission (Group 2), and 45 healthy controls. The study included quantitation of IRAK-3 methylation index (MI%), IRAK-3 mRNA, and myeloid differentiation factor88 (MyD88) and assessment of NF-κB activity. IRAK-3 MI% was significantly higher in group 1 compared to group 2, accompanied by lower IRAK-3 mRNA expression, elevated circulating MyD88, and increased NF-κB activity. IRAK-3 MI% correlated negatively with its transcript and positively with MyD88 and NF-κB activity. A logistic regression model was created to predict active demyelination. The C-index was 0.924, which indicates a very strong prediction model. Within the limitations of current work, IRAK-3 methylation level seems to be a promising candidate biomarker for identifying MS patients at risk of relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Associated KinasesMultiple SclerosisMyeloid Differentiation Factor 88HumansFemaleMaleAdultMiddle AgedCross-Sectional StudiesNF-kappa BRecurrenceRetrospective StudiesDNA MethylationBiomarkersRNA, MessengerYoung Adult

Stichwörter der Autor:innen

Active demyelinationIRAK-MInterleukin-1 receptor-associated kinase-3 (IRAK-3)Multiple sclerosisMyeloid differentiation primary response 88 (MyD88)Nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB)Relapse

Substanzen

Interleukin-1 Receptor-Associated KinasesMyeloid Differentiation Factor 88IRAK3 protein, humanNF-kappa BMYD88 protein, humanBiomarkersRNA, Messenger

Autor:innen und Institutionen

  • Clinical pathology department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Electronic address: mona.watany@med.tanta.edu.eg.
  • Msc Immunology from Tanta university, Faculty of Science, Tanta 31527, Egypt.
  • Medical biochemistry department, Faculty of Medicine. Tanta University, Tanta 31527, Egypt; Biochemistry Department, College of Medicine, Ha'il University, Ha'il 55211, Saudi Arabia.
  • Neurology department, Faculty of Medicine. Tanta University, Tanta 31527, Egypt.

Zitieren

APA

Watany, M. M., Elhosary, M. M., El-Horany, H. E., & El-Horany, M. E. (2024). Methylation of Interleukin-1 receptor-associated kinase-3 and the risk of multiple sclerosis relapse/activity. Clinical Immunology, 266, 110327. https://doi.org/10.1016/j.clim.2024.110327

Vancouver

Watany MM, Elhosary MM, El-Horany HE, El-Horany ME. Methylation of Interleukin-1 receptor-associated kinase-3 and the risk of multiple sclerosis relapse/activity. Clinical Immunology. 2024;266:110327. doi:10.1016/j.clim.2024.110327

BibTeX
@article{Watany2024,
  author = {Watany, Mona M and Elhosary, Marwa M and El-Horany, Hemat E and El-Horany, Mahmoud E},
  title = {Methylation of Interleukin-1 receptor-associated kinase-3 and the risk of multiple sclerosis relapse/activity},
  journal = {Clinical Immunology},
  year = {2024},
  volume = {266},
  pages = {110327},
  doi = {10.1016/j.clim.2024.110327}
}
Kostenlos starten →